🇺🇸 FDA
Patent

US 12049464

Compounds for targeted degradation of BRD9

granted A61KA61K45/06A61P

Quick answer

US patent 12049464 (Compounds for targeted degradation of BRD9) held by C4 THERAPEUTICS, INC. expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
C4 THERAPEUTICS, INC.
Grant date
Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K45/06, A61P, A61P35/00